Evoke submits drug application for diabetic gastroparesis nasal spray — 4 insights

Evoke Pharma submitted a new drug application to the FDA for its acute and recurrent diabetic gastroparesis nasal spray Gimoti. The spray relieves symptoms in adult women.

Here's what you should know:

1. Acute and recurrent diabetic gastroparesis primarily affects women. Approximately 80 percent of gastroparesis sufferers are women.

2. Existing oral treatments are ineffective during an acute flare. Evoke created its nasal spray as an treatment for those flare-ups.

3. Evoke President and CEO Dave Gonyer said, "We believe that Gimoti can make an important difference in the lives of these patients and we look forward to FDA approval."

4. The company expects a decision from the FDA by around August.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast